Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Operating Income (2016 - 2020)

Syndax Pharmaceuticals has reported Operating Income over the past 6 years, most recently at -$19.9 million for Q4 2020.

  • Quarterly results put Operating Income at -$19.9 million for Q4 2020, down 39.81% from a year ago — trailing twelve months through Dec 2020 was -$71.4 million (down 24.13% YoY), and the annual figure for FY2025 was -$273.1 million, up 19.6%.
  • Operating Income for Q4 2020 was -$19.9 million at Syndax Pharmaceuticals, roughly flat from -$19.9 million in the prior quarter.
  • Over the last five years, Operating Income for SNDX hit a ceiling of -$8.6 million in Q2 2016 and a floor of -$19.9 million in Q4 2020.
  • Median Operating Income over the past 5 years was -$15.3 million (2016), compared with a mean of -$15.5 million.
  • Biggest five-year swings in Operating Income: crashed 160.12% in 2016 and later increased 26.52% in 2019.
  • Syndax Pharmaceuticals' Operating Income stood at -$11.1 million in 2016, then tumbled by 74.93% to -$19.5 million in 2017, then grew by 0.8% to -$19.3 million in 2018, then increased by 26.52% to -$14.2 million in 2019, then crashed by 39.81% to -$19.9 million in 2020.
  • The last three reported values for Operating Income were -$19.9 million (Q4 2020), -$19.9 million (Q3 2020), and -$16.6 million (Q2 2020) per Business Quant data.